Health and Nutrition, Institute of Development Studies, University of Sussex, Brighton, England, United Kingdom of Great Britain.
Essential Medicines and Health Products, World Health Organisation, Geneva, Switzerland.
PLoS One. 2020 Feb 6;15(2):e0228201. doi: 10.1371/journal.pone.0228201. eCollection 2020.
Poor quality use of medicines (QUM) has adverse outcomes. Governments' implementation of essential medicines (EM) policies is often suboptimal and there is limited information on which policies are most effective.
We analysed data on policy implementation from World Health Organisation (WHO) surveys in 2007 and 2011, and QUM data from surveys during 2006-2012 in developing and transitional countries. We compared QUM scores in countries that did or did not implement specific policies and regressed QUM composite scores on the numbers of policies implemented. We compared the ranking of policies in this and two previous studies, one from the same WHO databases (2003-2007) the other from data obtained during country visits in South-East Asia (2010-2015). The rankings of a common set of 17 policies were correlated and we identified those that were consistently highly ranked.
Fifty-three countries had data on both QUM and policy implementation. Forty policies were associated with effect sizes ranging from +13% to -5%. There was positive correlation between the composite QUM indicator and the number of policies reported implemented: (r) = 0.437 (95% CI 0.188 to 0.632). Comparison of policy rankings between the present and previous studies showed positive correlation with the WHO 2003-7 study: Spearman's rank correlation coefficient 0.498 (95% CI 0.022 to 0.789). Across the three studies, five policies were in the top five ranked positions 11 out of a possible 15 times: drugs available free at the point of care; a government QUM unit; undergraduate training of prescribers in standard treatment guidelines, antibiotics not available without prescription and generic substitution in the public sector.
Certain EM policies are associated with better QUM and impact increases with co-implementation. Analysis across three datasets provides a policy short-list as a minimum investment by countries trying to improve QUM and reduce antimicrobial drug misuse.
药品质量差会产生不良后果。政府实施基本药物政策的效果往往并不理想,而且对于哪些政策最有效,我们知之甚少。
我们分析了来自世界卫生组织(世卫组织)2007 年和 2011 年调查的政策实施数据,以及来自发展中国家和转型国家 2006-2012 年调查的药品质量差数据。我们比较了实施和未实施特定政策的国家的药品质量差评分,并将药品质量差综合评分与实施政策的数量进行回归分析。我们比较了本研究与之前两项研究的政策排名,其中一项来自世卫组织相同的数据库(2003-2007 年),另一项来自东南亚国家访问(2010-2015 年)的数据。我们对一组共同的 17 项政策进行了排名,并确定了那些一直排名较高的政策。
53 个国家同时拥有药品质量差和政策实施数据。40 项政策的效果大小范围为+13%至-5%。综合药品质量差指标与报告实施政策的数量之间存在正相关关系:(r)=0.437(95%CI 0.188 至 0.632)。将本研究与之前研究的政策排名进行比较,显示与世卫组织 2003-2007 年研究存在正相关:Spearman 秩相关系数为 0.498(95%CI 0.022 至 0.789)。在这三项研究中,有五项政策在可能的 15 次中有 11 次排名前五:在护理点免费提供药物;政府药品质量差股;对开处方者进行标准治疗指南的本科培训、抗生素凭处方供应和公共部门的通用替代。
某些基本药物政策与更好的药品质量差相关,并且随着共同实施,效果会增加。对三个数据集的分析提供了一个政策简表,作为试图改善药品质量差和减少抗菌药物滥用的国家的最低投资。